The Effect of Oxytocin on Cognitive Rigidity and Social Anxiety in Eating Disorders
The Effect of Oxytocin on Cognitive Rigidity and Social Anxiety in Eating Disorders: A Randomized Placebo Controlled Trial of Oxytocin in the Treatment of Anorexia Nervosa
The Centre for Eating and Dieting Disorders (CEDD)
80 participants
Jan 6, 2012
Interventional
Conditions
Summary
The main purpose of this study is to ascertain whether inhaled oxytocin might have therapeutic potential in reducing the cognitive rigidity and social anxiety that have been shown to be important perpetuating factors in Anorexia Nervosa. Participants will be analysed to determine whether oxytocin brings about any improvements in thinking which might help patients with Anorexia Nervosa to recover more easily.
Eligibility
Inclusion Criteria1
- Participants who meet DSM-IV diagnostic criteria for Anorexia Nervosa will be included in the study. Participants suffering from common comorbidities of depression and anxiety and Axis II disorders will be included in the study.
Exclusion Criteria1
- Participants will be exluded from the trial if they are suffering from any other major conditions, apart from those related to anorexia nervosa (i.e. common comorbidities of depression, anxiety and Axis II disorders)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Oxytocin nasal spray - Participants will receive 2 daily doses of oxytocin (36 International Units per day) for the duration of the entire trial, 6 weeks. The oxytocin will be administered in 2 puffs, one to each nostril, twice a day, each puff containing 9 International Units of oxytocin.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12611000671965